1 / 14

Medco Health Solutions, Inc .

Medco Health Solutions, Inc. Yuqian (Annie) Zhang Piotr Chorzewski Nov. 18 th , 2004. Basic Facts. Split from Merck in August 2002 Share Price on August 21 st $25.57 36 shares x $38.76=$1,395.36 on Nov. 16 th 2004 Gain 51.58% P/E: 22.81 EPS: 1.7. Industry.

keegan-noel
Télécharger la présentation

Medco Health Solutions, Inc .

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Medco Health Solutions, Inc. Yuqian (Annie) Zhang Piotr Chorzewski Nov. 18th, 2004

  2. Basic Facts • Split from Merck in August 2002 • Share Price on August 21st $25.57 • 36 shares x $38.76=$1,395.36 on Nov. 16th 2004 • Gain 51.58% • P/E: 22.81 • EPS: 1.7

  3. Industry • Prescription Benefit Management • Customers base • Competitive environment • Business model • Industry controversy & litigations

  4. Stock performance

  5. Profitability

  6. Basic financial comparison - EPS

  7. Basic comparison – Gross Margin

  8. Basic comparison – Operating Margin

  9. SWOT Analysis • Strength • Top one in terms of absolute volume of mail orders • More than total of three largest competitors in 2003 • Mail order service typically reduces prescription drug costs by 8-10 percent • Weakness • Overall low growth with huge contract losses Sales growth2003-20022002-2001 Caremark 33% 21% Express Script 8% 42% Medco 4% 13.4% • Low profit margin • Impact from Merck

  10. SWOT Analysis • Opportunities • Aging population • Growing demand for generic and mail pharmacy • Threat • Competition from other PBM companies and retail pharmacies • Increasing prescription drug cost • Ongoing government probe of the company as well as the other PBMs

  11. Valuation-DCF Sales in $M Growth rate EBIT in $M EBIT margin Free cash flow Discount rate 8.9 9.8 10.7 Target price(constant growth) 41.9 35.7 30.9

  12. P/E=14 P/E=18 P/E=22 P/E=26 Valuation-Multiples Projected EPS

  13. Sensitivity analysis

  14. Recommendation-sell • Sell 36 shares of Medco at the market • Contingency plan if any interests in the industry • Monitor the progress of the legal issues in the industry in the near future • Perform valuation of other PBMs such as Caremark if do have confidence in the industry

More Related